Teva to repay $1.2B for Cephalon’s Conspiring with Generic Firms


Jeffrey Brennan emphasized the significance of a $1.2 billion FTC antitrust settlement on pay-for-delay antitrust drug claims, not only because the amount is “certainly a big number, and a billion is a lot of money,” but also because it is the first FTC case settled since the Supreme Court Actavis ruling on such claims. In future cases, Mr. Brennan added, « The Supreme Court’s rule of reason will apply, and the outcomes will be fact specific and dependent on the weight of the evidence. » Read the full article